Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

At the Cleveland Clinic, researchers are testing a preventive breast cancer vaccine, and results from Phase 1 of the trial are showing promising signs.

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Although great strides have been made in research for breast cancer vaccines, such a vaccine is likely years away from ...

Bang Bang” singer Jessie J, 37, has been center stage this year not just for her performances, but because she’s sharing her ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

Working the night shift, frequently flying across time zones or keeping an irregular sleep schedule does more than just leave ...

This week Dr. Diana Bitner shares the story of a man she met who is living with breast cancer, and why the holiday season can ...